<- All drugs

Danuglipron

DISCONTINUED

Oral non-peptide GLP-1 receptor agonist

graded results

ongoing records

effect domains

Evidence spread

High evidence 0Moderate evidence 2Low evidence 0Very low evidence 3

Danuglipron has a discontinued status in the scoped regulatory record below. Results describe observations and do not provide treatment advice.

Dated status sources

DISCONTINUED Global programme; Obesity; Oral tablet; as of 2026-07-13. Pfizer

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Danuglipron DISCONTINUED

pharmacology Decrease

Very low evidence

Oral non-peptide GLP-1RA (PF-06882961, Pfizer). Phase 2b twice-daily data showed clinically meaningful weight loss in obesity; once-daily formulation met PK...

Pfizer press release, 14 April 2025; STAT/CNBC/BioPharma Dive coverage Source

Full findingOral non-peptide GLP-1RA (PF-06882961, Pfizer). Phase 2b twice-daily data showed clinically meaningful weight loss in obesity; once-daily formulation met PK objectives. Development DISCONTINUED for weight management on 14 April 2025 after a single asymptomatic participant experienced potential drug-induced liver injury that resolved on discontinuation; Pfizer stated overall liver-enzyme elevation frequency across the >1,400 participant database was in line with approved class agents.

PopulationPhase 2b: adults with obesity (with/without T2D); >1,400 participant total safety database

Fundingindustry - Pfizer (trial sponsor; inferred from registration trial)

Comparatorsplacebo

Danuglipron DISCONTINUED

pharmacology Not directional

Very low evidence

Moderate hepatic metabolism / low intrinsic clearance in vitro; multiple phase I/II metabolites identified.

Jaiswal A et al. Comprehensive identification and characterization of in vitro and in viv... Source

PopulationIn vitro (human/rat liver microsomes, S9) and in vivo rat

Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Danuglipron DISCONTINUED

safety-other Increase

Very low evidence

Drug-induced liver injury signal leading to program discontinuation.

Pfizer press release: Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron, ... Source

PopulationPfizer dose-optimisation program (post phase 2b); chronic weight management

Fundingindustry - Pfizer (trial sponsor; inferred from registration trial)

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Danuglipron DISCONTINUED

Stomach and gut Increase

Moderate evidence

High GI adverse-event burden, dose-related, driving high discontinuation.

Buckeridge C et al. Efficacy and safety of danuglipron (PF-06882961) in adults with obesi... Source

PopulationPhase 2b N=628 (NCT04707313); 26/32 wk; placebo comparator

Fundingindustry - Pfizer

Comparatorsplacebo

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Danuglipron DISCONTINUED

weight-loss Decrease

Moderate evidence

Phase 2b: statistically significant, dose-dependent weight reduction vs placebo over 26/32 weeks.

Buckeridge C et al. Efficacy and safety of danuglipron (PF-06882961) in adults with obesi... Source

PopulationPhase 2b RCT (NCT04707313), N=628 randomised (536 danuglipron, 90 placebo), adults with obesity without diabetes; danuglipron BID; placebo comparator

Fundingindustry - Pfizer

Comparatorsplacebo